While Biogen didn't specify which of its collaborators licensed the IP, RocheÂ might fit the bill based on the size of the revenue and the scale of the cooperation with its anti-CD20 therapeutics programs.Another piece of the better-than-expected earnings puzzle is that Biogen reported $103 million in unrealized gains on its equity investments in Sangamo and Ionis Pharmaceuticals, clinical-stage collaborators in the company's Alzheimer's disease and ALS pipeline programs, respectively.